Blood neurofilament light chain in Parkinson's disease

Article Clinical Neurology

Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study

Monika Poetter-Nerger et al.

Summary: This study found that increased serum neurofilament light chain (NfL) levels were associated with PIGD subtype and PIGD scores in patients with advanced Parkinson's disease.

JOURNAL OF NEURAL TRANSMISSION (2022)

Add to Collection

Letter Clinical Neurology

Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)

Carsten Buhmann et al.

MOVEMENT DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease

Weifang Yin et al.

Summary: This study found that plasma neurofilament light chain (NfL) levels were associated with the severity of depression and anxiety in Parkinson's disease (PD) patients, and could potentially serve as a diagnostic biomarker for moderate to severe depression or anxiety in PD.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Neurosciences

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes

Emil Ygland Rodstrom et al.

Summary: This study examined the utility of serum neurofilament light chain (S-NfL) as a biomarker in late-stage Parkinson's disease (PD). The results showed significant correlations between S-NfL levels and disease progression milestones. Higher S-NfL levels were associated with poorer daily living activities and cognitive function. Combining S-NfL with clinical factors improved prognostic accuracy.

JOURNAL OF PARKINSONS DISEASE (2022)

Add to Collection

Review Clinical Neurology

Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice

Lars Toenges et al.

Summary: The clinical presentation of Parkinson's disease is complex and heterogeneous, making precise classification challenging. Currently, research is focused on investigating tissue- and fluid-based biomarkers to improve the understanding of Parkinson's disease. Blood-based biomarkers have great potential for use in clinical practice if they meet the necessary requirements. In this review, the knowledge on blood-based biomarkers for Parkinson's disease is summarized from both a researcher's and clinician's perspective.

JOURNAL OF NEURAL TRANSMISSION (2022)

Add to Collection

Article Clinical Neurology

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

Pascal Benkert et al.

Summary: sNfL is a biomarker of neuronal damage used in monitoring disease activity in multiple sclerosis patients. This study established a reference database to correct for age and BMI, showing sNfL's potential in identifying individuals at risk for future disease activity. The results suggest that sNfL Z scores could predict acute and chronic disease activity in multiple sclerosis patients, with higher Z scores indicating increased risk.

LANCET NEUROLOGY (2022)

Add to Collection

Article Neurosciences

Factors associated with mortality in early stages of parkinsonism

Anouke van Rumund et al.

Summary: Prognosis of patients with parkinsonism varies greatly between different syndromes and it is difficult to distinguish the different forms, especially in early stages. This study identified predictors of mortality and functional outcome in patients with recent-onset parkinsonism and established a simple prediction model. The model showed excellent performance in predicting functional outcome and mortality, and the findings were confirmed in an external validation cohort.

NPJ PARKINSONS DISEASE (2022)

Add to Collection

Article Clinical Neurology

Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface

Lisa Vermunt et al.

Summary: Interpretation of axonal damage biomarker NfL concentrations is challenging due to the lack of age-specific and disease-specific reference values. We developed an interactive interface to provide reference values and support clinicians in interpreting individual patient results in human body fluids.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson's disease

Don Gueu Park et al.

Summary: This study investigated the impact of non-motor markers on neuronal injury in early-stage Parkinson's disease, finding a correlation between OH, age, and disease duration with plasma NFL levels. It provides biomarker evidence for the association between OH and poor clinical outcomes in patients with PD.

JOURNAL OF NEURAL TRANSMISSION (2021)

Add to Collection

Article Neurosciences

Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders

Elena Diekaemper et al.

Summary: The study reveals a strong correlation between NfL and pNfH with pathological changes in presynaptic dopamine transporter density in the putamen concomitant to nigrostriatal degeneration.

FRONTIERS IN NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study

Rong Ye et al.

Summary: Research shows that serum NFL levels in Parkinson's disease patients are associated with motor decline and dopamine transporter loss, but not significantly related to cognitive decline. Higher serum NFL levels also predict progression of PIGD clinical features.

PARKINSONISM & RELATED DISORDERS (2021)

Add to Collection

Article Neurosciences

Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease

Ling-Zhi Ma et al.

Summary: The study found that serum NfL concentration can serve as an accessible biomarker for monitoring the severity and progression of cognitive decline in PD patients. Patients with PD had higher levels of serum NfL compared to healthy controls, and the increase in NfL levels was faster in the PD group. Baseline NfL levels and their rate of change were found to predict measurable cognitive decline in early PD, as well as future risk of PD dementia.

JOURNAL OF PARKINSONS DISEASE (2021)

Add to Collection

Article Clinical Neurology

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

Whitley W. Aamodt et al.

Summary: The study found that neurofilament light chain protein (NfL) is associated with cognitive function in Parkinson's disease (PD) patients and can predict future cognitive decline. Plasma NfL was identified as a useful prognostic biomarker for PD, predicting the likelihood of PD patients converting to mild cognitive impairment or dementia.

MOVEMENT DISORDERS (2021)

Add to Collection

Article Clinical Neurology